L'intérêt à découvert pour FS KKR Capital donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de FS KKR Capital. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

FS KKR Capital (NYSE:FSK) Stock, Rapport sur les intérêts à découvert

FS KKR Capital

FS KKR Capital Corp is a business development company based in the United States. Its portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies. It is focused on providing customized credit solutions to private upper middle-market companies, which it generally defines as companies with annual EBITDA of at least $50 million at the time of investment.

FS KKR Capital Corp

BMO Capital analyst Andrew Strelzik maintains Dave &amp; Buster's Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) with a Outperform and lowers the price target from $55 to $51.

News

Price Target

Analyst Ratings

PLAY

BMO Capital Maintains Outperform on Dave & Buster's Enter, Lowers Price Target to $51

Goldman Sachs analyst Kash Rangan maintains Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) with a Neutral and raises the price target from $72 to $86.

Goldman Sachs Maintains Neutral on Zoom Video Comms, Raises Price Target to $86

<a href="https://aon.mediaroom.com/2024-11-26-Aon-to-Acquire-In-House-Insurance-Agency-of-Mitsubishi-Chemical-Group-in-Japan">https://aon.mediaroom.com/2024-11-26-Aon-to-Acquire-In-House-Insurance-Agency-of-Mitsubishi-Chemical-Group-in-Japan</a>
&nbsp;
<a href="https://www.aon.com/">Aon plc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), a leading global professional services firm, today announced the signing of a definitive agreement to acquire the in-house insurance agency business of Mitsubishi Chemical Group (MCG) enhancing Aon's risk and health capability offering in Japan.
The in-house insurance agency operates as part of Dia Rix, an in-house business services provider to MCG. Aon will acquire the insurance agency business which provides corporate and personal lines insurance to MCG group companies and employees in Japan. The divestiture will allow MCG to divert resources and investment to its core business while leveraging the global risk management capabilities of Aon to strengthen its global governance.
Following the close of the transaction, the team will transition to Aon's brand and operating model, under the leadership of Tatsuya Yamamoto, head of Aon in Japan, bringing together a combined team of more than 400 colleagues.
Anne Corona, CEO for Aon in Asia Pacific said: "This acquisition reinforces our investment in Japan as an important market for Aon. The existing synergies we share with Dia Rix in terms of capability and culture will allow us to better serve MCG as well as strengthen broader capability and development opportunities for colleagues at the combined firm."
Tatsuya Yamamoto added: "The current changes in the non-life insurance environment in Japan will foster an environment in which global companies like the MCG can focus on their core business by divesting their in-house insurance agency operations, while at the same time supporting their operational efficiency strategies and leveraging a group of experts like Aon to provide an opportunity for more sophisticated global risk management. We are well situated to take this business forward building on our existing capabilities and growth momentum and continue to provide optimal solutions for all our clients in Japan."
The firms will continue to operate independently until the transaction is completed, which is expected in early 2025.

Global

Aon To Acquire In-House Insurance Agency Of Mitsubishi Chemical Group In Japan; No Financial Terms Disclosed

Looking into the current session, Hercules Capital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) shares are trading at $18.86, after a 0.37% decrease. Over the past month, the stock fell by 5.80%, but over the past year, it actually went up by 21.09%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1732631415_0.png" alt="Past Year Chart" />

<h3>How Does Hercules Capital P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Hercules Capital has a lower P/E than the aggregate P/E of 24.2 of the Capital Markets industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732631415_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

HTGC

Price Over Earnings Overview: Hercules Capital

Goldman Sachs analyst Ryan Nash maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Neutral and raises the price target from $59 to $67.

ZION

Goldman Sachs Maintains Neutral on Zions Bancorp, Raises Price Target to $67

Goldman Sachs analyst John Mackay maintains Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) with a Neutral and raises the price target from $45 to $55.

Goldman Sachs Maintains Neutral on Williams Companies, Raises Price Target to $55

Macro Economic Events

Econ #s

Economics

S&P/CS HPI Composite - 20 n.s.a. (MoM) For September -0.4% Vs -0.3% Prior

S&P/CS HPI Composite - 20 n.s.a. (YoY) For September 4.6% Vs 4.7% Est.; 5.2% Prior

President-elect Donald Trump dropped an economic bombshell Monday, announcing plans to slap hefty tariffs on key U.S. trade partners once he returns to the White House <a href="https://www.benzinga.com/topic/donald-trump">on Jan. 20. </a>
Trump pledged 25% tariffs on all Mexican and Canadian imports and an additional 10% levy on Chinese goods, which would remain in place until drugs, and in particular fentanyl, will stop entering the U.S.
&#8220;Thousands of people are pouring through Mexico and Canada, bringing crime and drugs at levels never seen before,&#8221; Trump wrote on Truth Social.
&#8220;On January 20th, as one of my many first executive orders, I will sign all necessary documents to charge Mexico and Canada a 25% tariff on ALL products coming into the United States. This tariff will remain in effect until such time as drugs, in particular Fentanyl, and all illegal aliens stop this Invasion of our country!&#8221;
<h3 class="wp-block-heading">Markets React: Peso And Loonie Hit Hard</h3>
Currency markets were the immediate shock absorber of the news. The Canadian dollar, tracked by the Invesco CurrencyShares Canadian Dollar Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXC#NYSE">FXC</a>), nosedived 0.8%, breaching the 1.41 level against the U.S. dollar — a low not seen since April 2020.
The Mexican peso didn't fare much better, sliding 0.9% to 20.50 against the greenback, while the Chinese yuan slumped 0.4% to a four-month low.
Robin Brooks, economist at the Brookings Institution, warned that this may only be the beginning. "The Mexican Peso is down 1.5% after tonight&#8217;s tariff news from the president-elect. To put this fall in perspective, the Mexican peso fell 10% in just a few days right after Trump's surprise win in 2016. So this fall is small and only the beginning of a sorely needed repricing."
The iShares MSCI Mexico ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWW#NYSE">EWW</a>) fell 1.5% in premarket trading on Tuesday.
James Thorne, a market strategist at Wellington Altus, questioned the practicality of Trump's rhetoric. "Do you really think Mr. Trump will put a 25% tariff on Canadian Sour Crude Oil?" Thorne wrote. "Recall it's mixed with Sweet Shale oil and then refined. Constraint of US refining capacity. Think about that for 1 minute."
<h3 class="wp-block-heading">China In The Crosshairs: Fentanyl And Tariffs</h3>
Trump renewed his criticism of China, blaming the country for America's fentanyl epidemic.
&#8220;I have had many talks with China about the massive amounts of drugs, in particular Fentanyl, being sent into the United States—But to no avail," Trump said. 
He accused Chinese officials of failing to deliver on promises to crack down on drug dealers, stating, "Until such time as they stop, we will be charging China an additional 10% tariff, above any additional tariffs, on all of their many products coming into the United States of America."
The tariffs, according to Trump, would serve as a dual-purpose weapon: curbing illegal drug imports and bolstering his "America First" economic policy.
<h3 class="wp-block-heading">Bill Ackman: Trump Is Using Tariffs As Weapon</h3>
Prominent investor Bill Ackman chimed in on X (formerly Twitter), suggesting that Trump's tariffs are less about trade and more about leverage. 
"To be clear, according to Trump, the 25% tariffs will not be implemented, or if implemented will be removed, once Mexico and Canada stop the flow of illegal immigrants and fentanyl into the U.S.," Ackman said. 
"In other words, Donald Trump is going to use tariffs as a weapon to achieve economic and political outcomes which are in the best interest of America, fulfilling his America First policy."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">To be clear, according to Trump the 25% tariffs will not be implemented, or if implemented will be removed, once Mexico and Canada stop the flow of illegal immigrants and fentanyl into the U.S. In other words, <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> is going to use tariffs as a weapon to achieve… <a href="https://t.co/61oQvCpW92">https://t.co/61oQvCpW92</a>
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1861198845574815947?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42170135/its-the-most-wonderful-time-of-the-year-for-the-stock-market-history-says">&#8216;It&#8217;s The Most Wonderful Time Of The Year&#8217; For The Stock Market, History Says</a></li>
</ul>
Photo: Shutterstock

Asia

Equities

Emerging Markets

Emerging Market ETFs

Currency ETFs

Politics

Forex

Mexican Peso, Canadian Dollar Slide As Ackman Says Trump Will Use Tariffs 'As A Weapon'

USA House Price Index (MoM) For September 0.7% Vs 0.3% Est.; 0.4% Prior

Goldman Sachs analyst Ryan Nash maintains Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) with a Buy and raises the price target from $50 to $60.

Goldman Sachs Maintains Buy on Truist Finl, Raises Price Target to $60

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more
GLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come
KELOWNA, BC / ACCESSWIRE / November 26, 2024 / Lexaria Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXXW#NASDAQ">LEXXW</a>) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following strategic update.
Today's GLP-1 drug market consists primarily of semaglutide (Wegovy&#xAE;, Ozempic&#xAE;, and Rybelsus&#xAE;), owned by Novo Nordisk&#xAE;; and tirzepatide (Zepbound&#xAE;, Mounjaro&#xAE;), owned by Eli Lilly&#x2122;. All five of those drug brands, with the exception of Rybelsus&#xAE;, are administered by injection, whereas Rybelsus&#xAE; is the only oral tablet currently approved by the FDA today. While these two drugs were originally approved by the FDA for diabetes management, weight-loss approvals soon followed and <a href="https://pr.report/4ja2">Wegovy&#xAE; was also approved by the FDA</a> in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke.
Acceptance and use of these two drugs by the public has resulted in unprecedented demand, with estimates of 2024 revenue between them of <a href="https://pr.report/4ja3">~$30 billion, compared to just $300 million in 2018</a>, an increase of 100x or 10,000%.

Biotech

General

LEXX

LEXXW

Lexaria Bioscience Provides Strategic Update; Says Semaglutide Being Investigated For Applications In Heart Disease, Alzheimer's, Liver Disease, And More; GLP-1 Drugs Expected To Generate Multi-Hundreds Of Billions Of Revenues In The Years To Come

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares are trading lower in the <a target="_blank" href="https://www.benzinga.com/24/11/42165679/nio-analyst-sees-tougher-path-to-profitability-downgrades-ev-maker-to-sell-what-you-need-to-know" rel="noreferrer noopener">premarket session on Tuesday.</a>
The Chinese EV manufacturer recently marked its 10th anniversary, with the company&#8217;s founder, chairman, and CEO, William Li, addressing employees through an internal letter.
In the message, Li emphasized the critical importance of the next two years for the company&#8217;s future, <a target="_blank" href="https://cnevpost.com/2024/11/25/nio-10th-anniversary-william-li-internal-letter/" rel="noreferrer noopener">reported</a> CnEV Post. Li outlined key objectives, including the launch of competitive new products and enhancing operational efficiency.
These efforts are aimed at doubling NIO&#8217;s sales in the coming year and achieving profitability by 2026, which he described as non-negotiable goals. Li urged the team to focus their full energy on meeting these targets.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42189572/j-m-smucker-q2-earnings-beat-17-sales-surge-fy25-eps-outlook-boost-more" rel="noreferrer noopener">J.M. Smucker Q2: Earnings Beat, 17% Sales Surge, FY25 EPS Outlook Boost &amp; More</a>
This week, Goldman Sachs analyst Tina Hou downgraded NIO from&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings" rel="noreferrer noopener">Neutral to Sell</a> and lowered the price target from&nbsp;$4.80&nbsp;to&nbsp;$3.90, citing competitive pressures <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings" rel="noreferrer noopener">and a difficult path to profitability ahead</a>.
The analyst notes NIO is unfavorably positioned heading into 2025 given the slow production ramp of&nbsp;Onvo and the company&#8217;s <a target="_blank" href="https://www.benzinga.com/tech/24/11/41703522/ev-maker-nio-marks-battery-swap-network-milestone-rumors-swirl-around-2nd-onvo-electric-suv" rel="noreferrer noopener">limited new model pipeline.</a>
Recently, NIO guided deliveries of 72,000–75,000 units for the fourth quarter, or a 43.9% – <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42084907/nio-q3-earnings-11-6-gain-in-vehicle-deliveries-margins-improve-issues-robust-q4-delivery-outlook" rel="noreferrer noopener">49.9% year-over-year increase.&nbsp;</a>
The company expects&nbsp;fourth-quarter revenue&nbsp;of $2.804 billion &#8211; $2.904 billion, representing 15.0% – 19.2% year-over-year growth.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, NIO stock has lost over 35% in the past year. Investors can gain exposure to the stock via&nbsp;Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>).
Price Action: NIO shares are trading lower by 1.29% to $4.61 premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades" target="_blank" rel="noreferrer noopener">Cathie Wood-Led Ark Invest&#8217;s Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Photo by Sundry Photography on Shutterstock.

Movers

Media

PowerShares Golden Dragon Halter USX China Portfolio

What's Going On With NIO Stock Today?

Goldman Sachs analyst Ryan Nash maintains Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Neutral and raises the price target from $52 to $62.

Goldman Sachs Maintains Neutral on Synovus Finl, Raises Price Target to $62

Goldman Sachs analyst Ryan Nash maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Buy and raises the price target from $29 to $33.

Goldman Sachs Maintains Buy on Regions Finl, Raises Price Target to $33

Goldman Sachs analyst Gabriela Borges maintains Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) with a Neutral and raises the price target from $19 to $21.

PYCR

Goldman Sachs Maintains Neutral on Paycor HCM, Raises Price Target to $21

Goldman Sachs analyst Ryan Nash maintains M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) with a Neutral and raises the price target from $216 to $243.

Goldman Sachs Maintains Neutral on M&T Bank, Raises Price Target to $243

Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) reported better-than-expected third-quarter results and raised its 2024 <a href="https://www.benzinga.com/quote/bbwi/earnings">outlook on Monday.</a>
BBWI&#8217;s third-quarter adjusted earnings per share of 49 cents, beating the analyst consensus of 47 cents. Quarterly sales of $1.610 billion, a growth of 3.1% year-over-year, above the street view of $1.579 billion.
Gina Boswell, CEO of Bath &amp; Body Works, commented, &#8220;Our strong results exceeded the high end of our net sales and earnings per diluted share guidance. As a result, we are raising our full-year guidance to fully reflect this outperformance.&#8221;
The company raised fiscal 2024 guidance and now expects net sales to decline 2.5% – 1.7% (prior view: decline of 4% – 2%), including a 100-basis-point headwind from the 53rd week in 2023. Adjusted earnings per share are projected at $3.15 – $3.28 (prior view $3.06 – $3.26) versus the $3.18 consensus.
Bath &amp; Body Works shares gained 16.5% to close at $35.78 on Monday.
These analysts made changes to their price targets on Bath &amp; Body Works following earnings announcement.
<ul>
<li>Piper Sandler analyst Korinne Wolfmeyer maintained Bath &amp; Body Works with a Neutral and raised the price target from $35 to $36.</li>
<li>Barclays analyst Adrienne Yih maintained Bath &amp; Body Works with an Underweight and raised the price target from $28 to $34.</li>
</ul>
Considering buying BBWI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-1024x562.png" alt="" class="wp-image-665566" style="width:658px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

Earnings

Trading Ideas

BBWI

Bath & Body Works Analysts Boost Their Forecasts After Strong Earnings

Emerald is a leading commercial vehicle manufacturer and seller of refrigerated trucks and vans
The refrigerated Class 3 EV box truck opens new rapidly expanding categories for home delivery, frozen food, grocery and beverage transportation
 &nbsp;
BREA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- via IBN -- <a href="https://www.globenewswire.com/Tracker?data=wFgf3qyya1KMke66r447VNDvrYRea54HMKKRkEIQo7Ly6CoQ822jOQuk85LNxNhZooU03MseZ8fDjALtlgbzIKIt_7OpXeZw6soRqa3qwxk=">Mullen Automotive, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) ("Mullen" or the "Company"), an electric vehicle ("EV") manufacturer, announces today that <a href="https://www.globenewswire.com/Tracker?data=_KqftE2Zw2BKCjE93TpWGt5-j6V6zVcnf-xlK3C_70G2VYB_cBF1YF-BHGPizrPq3GQMdfRLSGcKNe4KxVHmMzA-m4CuMgQqqHWVr8EjgONJBA1I_k_zte6g4XM-yxYU7UW6JQJchokpGnydx1lX_A==">Emerald Transportation Solutions</a> ("Emerald"), a premier commercial refrigeration ("reefer") vehicle upfitter, is working with the Papé Group ("Papé") to develop an advanced reefer upfit for the Mullen THREE, a Class 3 all-electric truck. The refrigerated Class 3 EV box truck opens new rapidly expanding categories for home delivery, frozen food, grocery and beverage transportation.

MULN

Mullen Announces  Emerald Transportation Solutions Is Working With The Papé Group To Develop An Advanced Reefer Upfit For The Mullen THREE, Class 3 All-Electric Truck

Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) will be reporting its third-quarter earnings on Tuesday. Wall Street expects $2.05 in EPS and $24.65 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=DELL" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 93.61% over the past year, 19.48% over the past month.
Let&#8217;s look at what the charts indicate for Dell stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/24/11/42189449/how-to-earn-500-a-month-from-dell-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Dell Stock Ahead Of Q3 Earnings</a>
<h2 class="wp-block-heading">Dell Technical Setup Ahead Of Q3 Earnings&nbsp;</h2>
Dell stock is showcasing a strong bullish trend, with its share price at $144.16 comfortably above the five-day, 20-day and 50-day exponential moving averages. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26084135/Screenshot-2024-11-26-at-6.02.20-PM.png" alt="" class="wp-image-665421" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26084135/Screenshot-2024-11-26-at-6.02.20-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26084135/Screenshot-2024-11-26-at-6.02.20-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
This upward momentum is reinforced by the eight-day simple moving average (SMA) of $137.40, the 20-day SMA at $134.40 and the 50-day SMA at $126.41, all pointing to continued bullish strength. 
Additionally, the stock remains well above its 200-day SMA of $122.23, underscoring long-term upward momentum.
However, while the Moving Average Convergence Divergence (MACD) at 4.36 confirms the bullish trend, and the RSI of 66.17 indicates strong buying momentum, the RSI&#8217;s proximity to overbought territory suggests a risk of bearish consolidation. 
Slight selling pressure also hints at potential near-term volatility. While the trend remains firmly bullish, investors should monitor for signs of cooling off as the stock approaches overbought levels.
<h2 class="wp-block-heading">Analysts See 7% Upside</h2>
Ratings &amp; Consensus Estimates: <a href="https://www.benzinga.com/quote/DELL/analyst-ratings" target="_blank" rel="noreferrer noopener">The consensus analyst rating</a> on Dell stock stands at a Buy currently with a price target of $121.73. Recent analyst ratings from Evercore ISI Group, Wells Fargo and Morgan Stanley suggest an average price target of $154.67 for Dell stock implying a 7% upside.
Price Action: Dell stock closed the trading day Monday at $144.16, down 0.03%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42185644/us-stocks-may-have-a-slow-start-as-trumps-tariff-threat-begins-to-thwart-relief-rally-analysts-remain-positive-on-market-breadth-ai-linked-sectors-and-stocks">US Stocks May Have A Slow Start As Trump&#8217;s Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Tech

DELL

Dell's 93% Rally Hits Q3 Crossroads – What's Next For The Stock?

How I Would Invest $10,000 In Today's Market

FS KKR Capital prices $600M unsecured notes

Dividend Harvesting Portfolio Week 193: $19,300 Allocated, $1,844.97 In Projected Dividends

RBC Capital analyst Kenneth Lee maintained a Hold rating on FS KKR Capital (FSK – Research Report) today and set a price target of $21.00. The comp...

FS KKR Capital (FSK) Receives a Rating Update from a Top Analyst

RBC Capital raised the firm's price target on FS KKR Capital (FSK) to $21 from $20 and keeps a Sector Perform rating on the shares. The company con...

FS KKR Capital price target raised to $21 from $20 at RBC Capital

Blackstone Secured Lending: A Growth BDC That Makes For A Good Long-Term Investment

My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys

Investing In BDCs For 10%+ Yields? This Is What Matters Now

FS KKR Capital ( ($FSK) ) has provided an update. FS KKR Capital Corp. has successfully completed a $600 million public offering of 6.125% unsecure...

FS KKR Capital Completes $600M Public Offering Successfully

71 November Graham Value All-Stars; Of 40 'Safer', Buy Any Of 30 Ideal Choices

AAPL

ABBV

AGNC

ALIZF

AMZN

ARCC

AVGO

BABA

BASFY

BAYZF

BBDC

BIZD

BLUE

BWLP

BXSL

CBAUF

CPAC

CSCO

CSWC

FDUS

GAIN

GAINZ

GILD

GLAD

GOOD

GOOG

GSBD

HIMX

INSW

INTC

JFIN

MAIN

MFIC

MPLX

MPLXP

MSDL

MSFT

NEWT

NVDA

OBDC

PANL

PEBO

RITM

SCHG

SCHW

SEMHF

SHEL

SITC

SPYI

STAG

STWD

TCPC

TPVG

TRMD

TSLA

TSLX

UNIT

VALE

VICI

Press Releases

FSK Announces Earnings Release and Conference Call Schedule for First Quarter 2024

Dividends

FS KKR Capital Corp. Announces First Quarter 2024 Results

Offerings

FSK Prices Public Offering of $600 million 6.875% Unsecured Notes Due 2029

FSK Completes Public Offering of $600 million 6.875% Unsecured Notes Due 2029

FSK Announces Earnings Release and Conference Call Schedule for Second Quarter 2024

FS KKR Capital Corp. Announces Second Quarter 2024 Results

FSK Announces Earnings Release and Conference Call Schedule for Third Quarter 2024; Declares Fourth Quarter 2024 Distribution of $0.70 per share

Insurance

FS KKR Capital Corp. Announces Third Quarter 2024 Results

FSK Prices Public Offering of $600 million 6.125% Unsecured Notes Due 2030

FSK Completes Public Offering of $600 million 6.125% Unsecured Notes Due 2030

Affiliated Managers Group, Inc. Common Stock

Affiliated Managers Group

Ameriprise Finl

Ares Capital Corporation - Closed End Fund

Ares Capital

Ares Management Corporation Class A Common Stock

Ares Management

Franklin Resources

The Bank of New York Mellon Corporation Common Stock

Bank of New York Mellon

BlackRock

Brookfield Corporation Class A Limited Voting Shares

Brookfield

Blackstone

Blackstone Secured Lending Fund Common Shares of Beneficial Interest

Blackstone Secured

Carlyle Group

Cohen & Steers

Hamilton Lane Incorporated - Class A Common Stock

Hamilton Lane

Invesco

Janus Henderson Group plc Ordinary Shares

Janus Henderson Group

Main Street Capital Corporation Common Stock

Main Street Capital

Northern Trust Corporation - Common Stock

Northern Trust

Blue Owl Capital Corporation Common Stock

Blue Owl Capital

Blue Owl Capital Inc. Class A Common Stock

Blue Owl Cap

SEI Inv

StepStone Group Inc. - Class A Common Stock

StepStone Group

State Street

T. Rowe Price Gr

RBC Capital

Comments

FS KKR Capital

Intérêt court

FS KKR Capital (NYSE:FSK) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL